Thirty-six (6.32%) stated that their first-degree relatives were vaccinated against Mmp11 HBV. In the cumulative analysis, only history of imprisonment was a statistically significant determinant of illness by HCV or HBV in opiate users. == Summary Lansoprazole == The current policy of screening only HIV-positive drug users for HBV and HCV in Iran misses most instances of HBV and HCV illness. We therefore recommend urgent revision of the nationwide protocol from the Ministry of Health in Iran to implement routine screening of all opiate users and especially IDU for these viruses, no matter their HIV status. == Intro == Iran offers one of the highest rates of opiate use in the world, and the use of opium and heroin improved in 2010 2010 compared to earlier numbers [1]. Among the population of Iran between the age groups of 15 and 64 years, 2.7% (1.1% to 5.9%) are estimated to use opiates [2]; 40% of these users consume opium, and the rest primarily consume heroin [3]. The main and most worrisome effect of opiate use is on health. Long-term opium use, actually at relatively low doses, is associated with an estimated 86% increase in the risk of death [4]. The mortality rate per million among drug users aged 15 to 64 years in Iran was estimated as 69.1, with the majority of deaths related to opiate use [5], compared to 5.4-48.6 per million in Asia and 22 to 55.9 per million worldwide [1]. Several risk factors make opiate users vulnerable to hepatitis C disease (HCV), hepatitis B disease (HBV) and human being immunodeficiency disease (HIV) and tuberculosis (TB) illness [6]. Risky behaviors include the use of nonsterilized needles by injection drug users (IDU) and unprotected sexual activities, unsafe tattooing, cupping, blood transfusion or dental care methods in both IDU and non-IDU [1,3]. In addition, lack of access to health solutions, low socioeducational level, history of imprisonment, sociable exclusion, homelessness, unemployment, alcohol dependency and having additional diseases complicate the picture of illness by HCV, HBV and HIV viruses and their related results in many opiate users [7]. The global prevalence of HCV illness among IDU in 2010 2010 was 46.7%, meaning that some 7.4 million of the 16 million IDU worldwide are infected with the hepatitis C virus. The HBV illness rate among IDU is about 14.6%, i.e., 2.3 million IDU are infected with this virus, and 18.9% or 3 million of IDU are living with HIV worldwide [1]. Despite the higher prevalence and transmissibility and the equal or higher health and economic costs of HCV compared to HIV illness, especially among IDU, viral hepatitis received far less attention than HIV-related Lansoprazole disease [8]. It is estimated that in Shiraz, a city having a human population 1.7 million, you will find about 32,520 (13249-71063) opiate users between the age groups of 15 and 64 years. There are also about 120 legal general public and private harm reduction, drug addiction-related and drop-in centers in Shiraz, but none of them display opiate Lansoprazole users for HCV or HBV illness. Not more than 2% of opiate users are referred annually to the only existing behavioral counseling center (BCC) affiliated with Shiraz University or college of Medical Sciences for free harm reduction solutions, and this center screens only IDU with HIV illness for HBV and HCV illness. As a result, most opiate users in the city are not screened for HCV and HBV illness. We carried out this study to measure the prevalence and determinants of HCV, HBV and HIV illness in all drug users including IDU and non-IDU in order to respond to the need for accurate, detailed data within the.